UC San Diego’s Rady School of Management finished up its tenth anniversary year on a lucrative note. In academic year 2013–14, the school’s graduates had a nearly $2 billion impact on the state of California and the San Diego region—from partnership agreements, to acquisitions, to funding events, to the first IPO by a Rady alum. Notable accomplishments included the acquisition of ecoATM by Outerwall for $350 million, the acquisition of Lumena Pharmaceuticals by Shire for $260 million, Inogen’s IPO for $70.5 million, and the partnering agreement between CytomX and Bristol-Myers Squibb for up to $1.2 billion.
Rady’s MBA program is tailored to professionals, often with science and technology backgrounds and an interest in innovation. Many go on to create viable start-up ventures, transform established firms, or work with small, entrepreneurial companies. In the school’s signature Lab2Market series of courses, entrepreneurs learn how to turn fledgling ideas into market opportunities.
The Bloomberg Businessweek’s 2014 full-time MBA ratings ranked the Rady School first nationally in the Intellectual Capital category. Intellectual capital is a measure of all articles published by faculty in twenty top business journals from 2009 to 2013.
Founded in 2003 as a start-up business school, Rady has already helped to launch eighty-two other start-ups. By thinking far beyond the scope of what is to what may be, the school’s graduates are shaping the innovation economy of the San Diego region and beyond, working on lifesaving medical advances and leveraging technology to enrich human life.